Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Teva Pharmaceutical Industries Limited

< Previous 1 2 3 4 5 Next >
Teva Announces Settlement with Lupin Resolving AUSTEDO® (deutetrabenazine) Patent Dispute
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRM
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva to Host Conference Call to Discuss First Quarter 2022 Financial Results at 8 a.m. ET on May 3, 2022
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tablets at 2022 American Academy of Neurology Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva Reaches Agreement With Florida to Settle the State’s Opioid-Related Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva Reaches Agreement With Rhode Island to Settle Opioid-Related Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva Reports Fourth Quarter and Full Year 2021 Financial Results
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva Reaches Agreement With Texas to Settle the State’s Opioid-Related Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Research Finds COVID Pandemic Worsened Health Equity Gap
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results and 2022 Financial Guidance at 8 a.m. ET on February 9, 2022
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva Statement Following New York Jury Ruling in Opioids Trial
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva Announces Launch of First-to-Market Generic Version of Narcan® (Naloxone Hydrochloride Nasal Spray), in the U.S.
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva Announces Launch of an Authorized Generic of Epiduo® Forte Gel (adapalene and benzoyl peroxide gel 0.3%/2.5%), in the U.S.
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva Announces Early Tender Results of its Debt Tender Offer, Increase of the Maximum Tender Amount and Election of Early Settlement
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva Announces Successful Upsize of Sustainability-Linked Senior Notes Offering and Pricing of $5,000,000,000 of Sustainability-Linked Senior Notes
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
California Judge Rules That Teva Did Not Cause a Public Nuisance or Make False or Misleading Statements About Opioids
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
New Phase 3 Data Presented at Psych Congress 2021 Showed TV-46000/mdc-IRM Significantly Prolonged Time to Impending Relapse Compared to Placebo in Patients with Schizophrenia
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva Announces $3,500,000,000 Debt Tender Offers for Notes Due 2022-2024
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva Announces Launch of $4,000,000,000 Offering of Sustainability-linked Senior Notes
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva Reports Third Quarter 2021 Financial Results
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva and MODAG Announce Licensing Collaboration for Neurodegenerative Disease Drug Candidate
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva to Present New Data from Growing Mental Health Portfolio at Psych Congress 2021
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva to Host Conference Call to Discuss Third Quarter 2021 Financial Results at 8 a.m. ET on October 27, 2021
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva to Present 8 Abstracts on AJOVY® (fremanezumab-vfrm) Injection and Hold Symposium on Healthcare Disparities at WCN
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva Enlists Sarah Michelle Gellar to Launch “Inhaler Tales” Campaign to Raise Awareness About Inhaler Use in Asthma and COPD
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva Reaches Agreement with Louisiana to Settle the State’s Opioid-Related Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Late-Breaking Data at the International Headache Society & European Headache Federation Joint Congress 2021 Showed AJOVY® (fremanezumab-vfrm) Injection Reduced More Monthly Migraine Days in a Network Meta-Analysis Study with Atogepant and Rimegepant
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Showcasing Teva’s Commitment to Helping Patients Have More Migraine-Free Days, 18 Abstracts will be presented, Including One Late-Breaker, on AJOVY® (fremanezumab-vfrm) Injection at the International Headache Society and European Headache...
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva Announces Post Hoc Analysis of Long-Term Data Examining Treatment with AUSTEDO® (deutetrabenazine) Tablets in Adult Patients with Tardive Dyskinesia
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.